Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Neurol Ther · 2022 · PMC9338201 · PMID 35713760

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results in the Chinese subpopulation showed a trend consistent with that observed in the primary cohort [ 16 ] across all primary and secondary endpoints, as demonstrated in Fig. 2 and Supplementary Table 1.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.